Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue Responsible Steps Prior Auth | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFlorida BluePolicy N/A

    Responsible Steps Program prior authorization and prerequisite (step) therapy criteria for specialty and behavioral health drugs

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines drugs included in Florida Blue's Responsible Steps Program and prerequisite (step) drug use requirements that must be met for authorization; applies to providers prescribing the listed specialty/behavioral health drugs for members covered by Florida Blue.

    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Steps Program prior authorization and prerequisite (step) therapy criteria for specialty and behavioral health drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior-use documentation showing trials of required generic medications (typically two distinct generics for antidepressants/antipsychotics; indication-specific alternatives or one generic for Lybalvi) on the program authorization form.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    multiplelisted target drugs
    2typical prior generic trials required
    1Lybalvi exception
    drug-specificindication-specific lists

    Coverage / Prior Authorization Criteria

    inv-01: Prerequisite (step) therapy criteria

    Covered when ALL of the following prior-use conditions appropriate to the indication are met:

    Behavioral health / Antidepressant prerequisites: Previous use of two or more generic versions of bupropion, citalopram, desvenlafaxine succinate ER (generic Pristiq), duloxetine, escitalopram (tablets or solution), fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine (including ER), or vilazodone.>=2 generics

    Applies to many antidepressant target drugs listed in the Responsible Steps Program.

    Neuropathic pain prerequisites: If the indication is neuropathic pain: previous use of one or more of amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline.>=1 generic appropriate to neuropathic pain

    Use this branch when the requested drug is for neuropathic pain.

    Policy Summary
    PayerFlorida Blue
    PolicyResponsible Steps Program prior authorization and prerequisite (step) therapy criteria for specialty and behavioral health drugs
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior-use documentation showing trials of required generic medications (typically two distinct generics for antidepressants/antipsychotics; indication-specific alternatives or one generic for Lybalvi) on the program authorization form.
    SourceLink
    On This Page
    Coverage / Prior Authorization CriteriaInitial Therapy / Prior TrialsStep Therapy / Required Prior Trials (Tables)Provider Requirements & Authorization ProcessDefinitions & Key TermsBackgroundRevision History
    Fibromyalgia prerequisites: If the indication is fibromyalgia: previous use of one or more of amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.>=1 generic appropriate to fibromyalgia

    Use this branch when the requested drug is for fibromyalgia.

    Chronic musculoskeletal pain prerequisites: If the indication is chronic musculoskeletal pain: previous use of one or more of acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an oral or topical NSAID, or tramadol.>=1 generic or alternative appropriate to chronic musculoskeletal pain

    Use this branch when the requested drug is for chronic musculoskeletal pain.

    Antipsychotic prerequisites: Previous use of two or more generic versions of aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.>=2 generics (except Lybalvi)

    For antipsychotic target drugs a trial of two or more generics is generally required; Lybalvi is an explicit exception and requires only one prior generic trial.

    inv-02: Prerequisite trials by indication

    Coverage is conditioned on prior use of specified generic medications or indication-specific alternative agents:

    General antidepressant prerequisite (OR branches): Previous use of listed generic antidepressants (bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine/ER, or vilazodone); OR, if the drug is requested for neuropathic pain, prior use of amitriptyline/desipramine/duloxetine/gabapentin/imipramine/nortriptyline; OR, if for fibromyalgia, prior use of amitriptyline/cyclobenzaprine/desipramine/duloxetine/gabapentin/imipramine/nortriptyline/tramadol; OR, if for chronic musculoskeletal pain, prior use of acetaminophen/amitriptyline/cyclobenzaprine/desipramine/duloxetine/gabapentin/imipramine/nortriptyline/NSAID (oral or topical)/tramadol.clinical-indication dependent

    OR branches are indication-specific prerequisites.

    inv-04: Prerequisite prior-use criteria

    For many antipsychotic target drugs prior generic trials are required:

    citations=[

    Coverage of drugs included in Florida Blue’s Responsible Steps Program is contingent on documented prior medication trials. For antidepressant target drugs, the policy generally requires prior trials of two or more generic versions from the listed antidepressant options (examples include bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine/venlafaxine ER, and vilazodone). (See the program’s therapeutic-category authorization form for the full target list.)

    When the requested indication is pain-related rather than primary antidepressant treatment, indication‑specific prerequisite lists apply: for neuropathic pain the prior-use requirement is previous trial of one of the listed agents (for example, amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline); for fibromyalgia the prior-use list includes agents such as amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol; and for chronic musculoskeletal pain prerequisite options include acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an NSAID (oral or topical), or tramadol. These indication-specific alternatives satisfy the program prerequisite when the target drug is being used for that condition.

    For many antipsychotic target drugs the policy requires prior trials of two or more generic antipsychotics from the enumerated list (examples: aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). An explicit exception is Lybalvi, which requires documentation of only one prior generic antipsychotic instead of two.

    Gabapentin extended‑release (ER) products (Gralise, generic Gralise, Horizant) are included in the program; prior documented use of generic immediate‑release gabapentin is noted as a prerequisite in the program language where gabapentin ER is the requested product.

    Providers seeking authorization must submit clinical documentation showing the prior medication trials appropriate to the indication (the number of distinct generic trials depends on the target drug and its class — typically 2 or more generics for many antidepressant/antipsychotic targets, with the Lybalvi exception: 1 generic). Failure to document the required prior trials may result in denial of authorization.

    Lybalvi is treated as an exception in the Responsible Steps Program: unlike most listed antipsychotic target drugs that require prior trials of two or more generic antipsychotics, Lybalvi requires documentation of only one prior generic antipsychotic.

    This Lybalvi exception is repeated throughout the program text; when Lybalvi is the requested target drug, submit documentation showing at least one prior trial of a listed generic antipsychotic to meet the prerequisite step‑therapy requirement.

    All other antipsychotic and many antidepressant targets retain the standard prerequisite: prior documented use of two or more generics from the enumerated lists unless another indication‑specific alternative list applies (e.g., neuropathic pain, fibromyalgia, chronic musculoskeletal pain).

    The policy provides indication‑specific prior‑use alternatives and does not list explicit coverage exclusions in these sections. Instead, authorization is conditioned on meeting the appropriate prerequisite medication trials for the indication. For antidepressant indications the prerequisite is generally prior trials of two or more listed generic antidepressants; for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain one prior trial from the condition‑specific lists will satisfy the prerequisite for that indication.

    There are no separate clinical exclusions stated in the excerpted coverage criteria text; the focus is on documenting the required prior medication history appropriate to the requested drug and indication.

    If the required prior trials are not documented (for example, two distinct generic trials where specified, or the appropriate indication‑specific generic), the policy’s review process may deny authorization for the target drug rather than list a formal exclusion.

    The coverage criteria across the Responsible Steps Program repeatedly require evidence of prior medication trials; no separate exclusions are enumerated in the provided segments. The relevant enforcement is via prerequisite documentation: prior trials of the listed generic medications (number and class depending on the target drug and indication) are required before the target branded or ER/specialty agent will be authorized.

    For gabapentin ER products (Gralise, Horizant) the program text specifically references prior use of generic immediate‑release gabapentin as a prerequisite in some contexts; this is a product‑specific prerequisite rather than an exclusion.

    Exceptions such as Lybalvi (requires only one generic prior trial) are explicitly noted in the criteria rather than treated as coverage exclusions.

    This section consolidates the prerequisite trial logic: for most antidepressant target drugs, authorization requires prior trials of two or more generic antidepressants from the enumerated list. When the requested indication is neuropathic pain, fibromyalgia, or chronic musculoskeletal pain, prior use of one of the indication‑specific generic alternatives is sufficient to meet the prerequisite for that condition.

    For antipsychotic targets, the standard requirement is prior documented use of two or more generic antipsychotics from the listed options. The policy explicitly states the Lybalvi exception: Lybalvi requires only one prior generic antipsychotic trial.

    For gabapentin ER requests, the policy references prior use of generic immediate‑release gabapentin as a prerequisite in contexts where gabapentin ER is the target product; providers should document that prior IR gabapentin trial when seeking authorization for ER formulations.

    Providers must submit clinical documentation of the prior trials appropriate to the indicated diagnosis and target drug. Absence of the required prior‑use documentation (e.g., lack of two distinct generic trials where required) may result in denial of the authorization request.

    Coverage for Responsible Steps Program target drugs follows a step‑therapy approach: generally, prior trial and failure (or intolerance) of two or more generic agents from the relevant therapeutic lists is required before a branded or ER target drug will be authorized.

    Indication‑specific alternative prior‑use lists provide acceptable prior medications when the target drug is being prescribed for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain; in these cases one prior trial from the condition‑specific list satisfies the prerequisite.

    The program text repeatedly highlights the Lybalvi special case: for Lybalvi only one prior generic antipsychotic is required instead of the usual two.

    Initial Therapy / Prior Trials

    inv-110: Initial therapy prior-use

    Initial coverage requires prior trials of generics in the same therapeutic category.

    General initial therapy requirement: Prior use of two or more generic versions of listed antidepressants for antidepressant-target drugs; or prior use of the listed generics specific to the pain indication as detailed.two or more generics (antidepressants) or specified alternatives for pain

    Lybalvi exception: one generic required

    inv-111: Initial therapy prior-use rules

    Initial coverage contingent on prior generic use

    Initial prior-use requirement: Document previous use of required generic drugs per indication prior to approval of target branded drug.see lists

    See therapeutic-specific lists in this section

    inv-112: Prerequisite step therapy for initial authorization

    Initial authorization prerequisites

    General antidepressant target drugs: Previous use of two or more generic antidepressants from the specified list.two or more generics

    Applies to many target antidepressant drugs listed in the program.

    Antipsychotic target drugs: Previous use of two or more generic antipsychotics from the specified list (Lybalvi exception: one generic required).two generics (one for Lybalvi)

    Applies to listed antipsychotic target drugs.

    inv-113: Initial therapy prerequisites

    Initial prerequisite therapy expectations (by indication)

    Initial antidepressant therapy: Previous use of generic antidepressants listed (see antidepressant list).

    Chunk 205

    inv-114: Initial therapy prior-use

    Initial authorization requires documented prior trials of listed generics based on indication.

    Initial prior-use requirement: Documented previous use of the specified generic drugs (number and specific agents depend on target drug and indication)as specified per drug/indication

    see program lists

    inv-115: Initial therapy prior trials

    Initial authorization requires prior trials of generics appropriate to indication.

    Initial antidepressant requirement: Two or more generic antidepressant trials required before target antidepressant authorization.two_or_more

    Chunk 255-256 lists the antidepressants.

    Step Therapy / Required Prior Trials (Tables)

    Step requirementRequired prior trial(s)
    Behavioral health — antidepressant targets
    Previous use of two or more generic versions of bupropion, citalopram, desvenlafaxine succinate ER (generic Pristiq), duloxetine, escitalopram (tablets or solution), fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine (including ER), or vilazodone.
    Step requirementRequired prior trial(s)
    Neuropathic pain indication
    Previous use of one or more of: generic amitriptyline, desipramine, duloxetine, gabapentin (immediate‑release), imipramine, or nortriptyline.
    Step requirementRequired prior trial(s)
    Fibromyalgia indication
    Previous use of one or more of: generic amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.
    Step requirementRequired prior trial(s)
    Antipsychotic targets (general)
    Previous use of two or more generic versions of aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone is required. Exception: Lybalvi requires documented prior use of only one generic antipsychotic.
    Step requirementRequired prior trial(s)
    Chronic musculoskeletal pain indication
    Previous use of one or more of: generic acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an NSAID (oral or topical), or tramadol.
    Step requirementRequired prior trial(s)
    General step-therapy rule
    Require prior trials of two or more generic versions of listed antidepressants or antipsychotics for most target drugs; Lybalvi is an exception and requires only one prior generic trial.
    Step requirementRequired prior trial(s)
    Antipsychotic-specific prior trials
    For many antipsychotic target drugs, documented prior use of two or more generic antipsychotics from the listed group is required; Lybalvi requires only one generic prior trial.
    Step requirementRequired prior trial(s)
    Antidepressant targets — indication alternatives
    Previous use of two or more generic antidepressants from the listed group OR, depending on indication, previous use of the applicable pain‑indication generics (see neuropathic pain, fibromyalgia, chronic musculoskeletal pain lists).
    Step requirementRequired prior trial(s)
    Documentation requirement
    Providers must document prior trials of the listed generic medications appropriate to the indication; number required varies by drug/indication (typically two or more generics for antidepressants/antipsychotics; one generic for certain indications or Lybalvi).
    Step requirementRequired prior trial(s)
    Program-wide prior-use expectation
    Coverage of Responsible Steps Program target drugs is conditioned on documented prior use as specified per indication (e.g., two or more generic antidepressant trials for antidepressant targets; indication‑specific alternatives for pain conditions).
    Step requirementRequired prior trial(s)
    Gabapentin ER-specific requirement
    Prior use of generic immediate‑release gabapentin is required before coverage of gabapentin ER formulations (Gralise/Horizant) as noted.
    Step requirementRequired prior trial(s)
    Required evidence for authorization
    Prior authorization requires documentation of prior use of the specified generic agents (lists vary by therapeutic category and indication); absence of documented trials may result in denial.
    Step requirementRequired prior trial(s)
    Summary — antidepressant generics list
    Previous use of two or more generic versions of: bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine (including ER), or vilazodone.
    Step requirementRequired prior trial(s)
    Antipsychotic targets — Lybalvi exception noted
    Prior trials of two or more generic antipsychotics from the listed group are required before approval of many antipsychotic targets; Lybalvi requires only one prior generic trial (exception explicitly stated).
    Step requirementRequired prior trial(s)
    Indication-specific prerequisite summary
    Apply the listed prior‑use options per indication: antidepressant targets generally require two or more generic antidepressant trials; if the indication is neuropathic pain, fibromyalgia, or chronic musculoskeletal pain use the corresponding alternative generic lists shown.

    Provider Requirements & Authorization Process

    Prior Authorization

    Responsible Steps Program prior authorization

    Drugs listed in Florida Blue’s Responsible Steps Program (including many antidepressants, antipsychotics, and gabapentin ER products) require prior authorization under the program; prescribers must submit an authorization request using the program-specific forms referenced on the payer’s Authorization Forms page.

    • Target drugs include numerous antidepressants, antipsychotics, and gabapentin ER (examples: Cymbalta, Abilify, Lybalvi, Gralise/Horizant).
    Prior Authorization

    Prior authorization requires prerequisite trials

    Prior authorization requests must include evidence that prerequisite medication trials have been met per the Responsible Steps Program; target drug coverage is conditioned on these prerequisite trials.

    • Prerequisite trial expectations vary by therapeutic category and indication (see indication‑specific lists).
    Note

    Link to Authorization Forms for Responsible Steps Program

    Authorization forms for the Responsible Steps Program are available on the payer’s Authorization Forms page; providers must search for and select the document matching the therapeutic category of the requested drug (example: select 'Antidepressants' for Cymbalta).

    • Use the Authorization Forms link and choose the therapeutic‑category document when completing a prior authorization.
    Documentation Required

    Prior use required for authorization

    Authorization requires documentation of prior use of the specific generic agents appropriate to the indication (behavioral health or indication‑specific pain lists) as listed in the program criteria.

    • For antidepressant/behavioral health indications, list of generics includes bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine (including ER), or vilazodone.
    • For pain indications, see the neuropathic pain, fibromyalgia, or chronic musculoskeletal pain prerequisite lists.
    Step Therapy

    Generic prior-use requirement

    Many target drugs require documented prior use of two or more generic versions of agents in the relevant therapeutic class before approval; exceptions to the two‑generic requirement are specified in the policy.

    • Typical requirement: previous trials of two or more generics for many antidepressant and antipsychotic targets.
    Prior Authorization

    Prior authorization required for target drugs

    Certain branded products listed as program 'target drugs' will not be authorized without prior authorization and demonstration of the prerequisite generic trials specified for that product and indication.

    • Examples of target drugs are listed throughout the program document (e.g., Abilify, Seroquel, Cymbalta, Gralise/Horizant).
    Prior Authorization

    Prior authorization requirement

    Prior authorization approvals are contingent upon documentation showing prior use of the specified generic alternatives appropriate to the indication; this includes behavioral‑health generics or indication‑specific pain agents as listed.

    • If the indication is neuropathic pain, previous use of amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline must be documented.
    • If fibromyalgia or chronic musculoskeletal pain is the indication, the respective prerequisite lists apply.
    Documentation Required

    Prior use of generics required

    Providers must document prior use of the specified generic agents (see the program lists) for the relevant indication (depression/antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) when submitting authorization requests.

    • Clinical documentation should reflect prior trials of the listed generics appropriate to the diagnosis being treated.
    Step Therapy

    Antipsychotic generic-trial requirement

    For many antipsychotic target drugs, prior authorization requires documented prior use of two or more generic versions of listed antipsychotics; Lybalvi is explicitly noted as an exception that requires only one prior generic trial.

    • Antipsychotic generics listed include aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone.
    Documentation Required

    Prior authorization requires documented prior drug trials

    Prior authorization must include documentation of prior drug trials demonstrating use of the listed generic agents before coverage will be granted for target drugs included in the Responsible Steps Program.

    • Refer to the program’s authorization form for the therapeutic category to indicate which prior‑use evidence is provided.
    Prior Authorization

    Program prior authorization

    Prescribers must submit authorization requests that demonstrate the prerequisite generic trials per the program criteria for the requested target drug and indication.

    • Use the program authorization form for the drug’s therapeutic category and include prior‑use history.
    Prior Authorization

    Prior authorization required for program drugs

    Drugs included in the Responsible Steps Program require prior authorization using the program‑specific authorization forms; providers must demonstrate prerequisite generic trials as specified by indication.

    • Examples of included products and the need for prior‑use documentation are listed in the program document.
    Prior Authorization

    Prior authorization required

    Prior authorization approval depends on evidence of prior use of the listed generic agents appropriate to the specific indication; Lybalvi is an exception requiring only one prior generic trial.

    • Documentation must indicate which prerequisite list applies based on the diagnosis (antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain).
    Documentation Required

    Prerequisite prior medication use

    Submit documentation showing prior use of the specific generic agents listed for the relevant indication (behavioral‑health antidepressants/antipsychotics or indication‑specific analgesics) when requesting authorization.

    • Include prior‑use history demonstrating trials of the listed generics; the number of distinct generics required varies by target drug (commonly two; Lybalvi exception noted).
    Step Therapy

    Prerequisite generic trials required

    Prior authorization requires documented previous use of the specified generic agents from the program’s prerequisite lists before the target branded agents will be covered.

    • For gabapentin ER products, prior use of immediate‑release gabapentin is noted as a prerequisite in the program.
    Documentation Required

    Prior authorization prerequisite: prior-use trials

    Prior authorization requests must document previous use of the specified generic alternatives appropriate to the indication; for gabapentin ER formulations this includes prior use of immediate‑release gabapentin.

    • Search and use the authorization form for the therapeutic category when submitting evidence.
    Documentation Required

    Prior use of generics required

    Prior authorization requires documentation showing prior use of two or more generic versions of listed antidepressants (or other specified prior drugs depending on indication); providers must reference the program lists when submitting requests.

    • Indication‑specific alternative prior agents apply for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.
    Step Therapy

    Prerequisite drug trials

    Step‑therapy logic: many target drugs require prior use of two or more generic alternatives from the same therapeutic class; Lybalvi is an explicit exception requiring only one prior generic trial.

    • The program defines step requirements by indication and drug class—follow the listed generic‑trial counts.
    Step Therapy

    Step therapy/prerequisite trial requirements

    Step therapy for Responsible Steps Program drugs requires prior trials of the specified generics depending on indication; many target drugs require two or more generic trials while some indication branches accept one appropriate alternative agent.

    • Indication‑specific lists include neuropathic pain, fibromyalgia, and chronic musculoskeletal pain alternatives.
    Step Therapy

    Step therapy/prerequisite trials

    Step‑therapy requirement: previous use of two or more generic versions of listed antipsychotics or antidepressants is generally required for authorization; Lybalvi requires only one prior generic trial.

    • Document prior trials of the required number of distinct generics per the program lists.
    Step Therapy

    Step therapy by indication

    Step therapy requires prior trials of the specified generic agents by indication: antidepressant list for behavioral‑health indications; neuropathic pain list (amitriptyline, desipramine, duloxetine, gabapentin, imipramine, nortriptyline); fibromyalgia list (amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, tramadol); chronic musculoskeletal pain list (acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, NSAID, or tramadol).

    • Use the branch that corresponds to the member’s diagnosis when documenting prior trials.
    Step Therapy

    Generic-step prerequisite

    Many target drugs require prior trial and failure of two or more generic alternatives from the same therapeutic class before approval; Lybalvi requires only one generic prior trial.

    • Ensure documentation specifies the distinct generic products tried and dates/duration of therapy as evidence.
    Step Therapy

    Step/prerequisite therapy

    Step therapy functions as a prerequisite—providers must show prior use of two or more generics from the specified therapeutic lists (exceptions noted for some drugs/indications).

    • Lybalvi is identified as requiring only one prior generic trial.
    Step Therapy

    Indication-specific prerequisite trials

    Step therapy requires prior trials of specified generics depending on indication; for neuropathic pain the required prior agents include amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline.

    • Document which neuropathic‑pain agent was used previously when submitting authorization.
    Step Therapy

    Antipsychotic step requirement

    For many antipsychotic target drugs, prior authorization requires documented use of two or more generic antipsychotics from the listed agents; Lybalvi is an exception requiring only one prior generic trial.

    • Listed antipsychotic generics include aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone.
    Step Therapy

    Generic step therapy requirement

    Step therapy generally requires prior use of two or more generic versions of listed antidepressants or antipsychotics before a target drug is authorized; Lybalvi is consistently noted as requiring only one generic prior trial.

    • Follow the program lists and indicate any exceptions (e.g., Lybalvi) on the authorization form.
    Step Therapy

    Generic trial/step requirements

    Step‑therapy requirements include prior use of two or more generic antidepressants (examples listed) OR indication‑specific alternatives for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain; many antipsychotics require two generics (Lybalvi exception).

    • Examples of antidepressant generics: bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, venlafaxine (including ER), vilazodone.
    Step Therapy

    Step therapy / prerequisite drugs

    Step therapy requires prior use of the specified generic alternatives before coverage of target drugs; typical requirement is previous use of two or more generics, with indication‑specific alternative lists provided.

    • Providers should document trials and outcomes (e.g., treatment failure or intolerance) per usual authorization documentation practices.
    Step Therapy

    Step/sequence requirements

    Step requirements for many antipsychotics and antidepressants require prior use of two or more generic versions of listed agents; Lybalvi is an explicit exception requiring only one prior generic trial.

    • When requesting Lybalvi, include documentation of a single prior generic antipsychotic trial as specified.
    Step Therapy

    Step requirements for antipsychotics/antidepressants

    For many antipsychotics and antidepressants, prior authorization will require documentation of two or more prior generic trials from the listed agents; indicate Lybalvi’s single‑generic exception when applicable.

    • Ensure prior trials are distinct generic products as required by the policy language.
    Step Therapy

    Step therapy/Prerequisite drugs

    Step therapy requires prior trials of two or more generic versions of listed antidepressants or antipsychotics before coverage of target drugs; exceptions (such as Lybalvi requiring only one generic trial) are noted in the policy.

    • Document prior trials clearly on the authorization form, including dates and reason for discontinuation if applicable.
    Step Therapy

    Step therapy prior trials

    Step‑therapy logic: providers must demonstrate prior trials of two or more generic alternatives (specific lists provided) before target drugs are authorized; Lybalvi requires only one prior generic trial.

    • Submit prior‑use history with the authorization to show the required number of distinct generic trials.
    Documentation Required

    Documentation of prior trials

    Providers must document prior use(s) of the specified generic medications appropriate to the indication (behavioral health or indication‑specific pain lists) when submitting an authorization request.

    • Documentation should reflect which agents were tried, dates of therapy, and reason for discontinuation or failure.
    Documentation Required

    Required prior-medication documentation

    Authorization documentation must show previous use of the specified generic medications or alternative agents depending on the indication (examples: two or more generic antidepressants for behavioral‑health targets; specified tricyclics/SNRI/gabapentin for neuropathic pain).

    • Include the specific agent names and treatment dates to meet the program’s prerequisite documentation requirements.
    Documentation Required

    Required prior-use documentation

    Clinical documentation must show prior use of the specific generic medications listed for the relevant indication (behavioral health antidepressants/antipsychotics or the appropriate pain agents) to meet the program prerequisites.

    • When the indication is neuropathic pain, documentation must indicate prior use of agents such as amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline.
    Note

    Authorization forms

    The Authorization Forms page contains the program forms for all Responsible Steps Program drugs; providers must search for and use the form that matches the therapeutic category of the drug being requested.

    • Example: select the 'Antidepressants' authorization document for requests involving Cymbalta or other antidepressant targets.
    Documentation Required

    Required prior-use documentation

    Documentation must show prior use of specified generic agents appropriate to the drug class and indication (see the indication‑specific prerequisite lists for neuropathic pain, fibromyalgia, and chronic musculoskeletal pain).

    • For fibromyalgia, acceptable prior agents include amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.
    Documentation Required

    Required prior-use documentation

    Documentation must demonstrate prior use of the specific generic drugs listed for the relevant indication (antidepressants list OR the indicated pain agent lists) before the target drug will be authorized.

    • Include dates, trial duration, and reason for discontinuation or inadequate response where relevant.
    Billing Rule

    Authorization form location

    Providers should reference the Authorization Forms page and select the document matching the therapeutic category when submitting authorization requests; include the required prior‑use evidence from the program lists.

    • Attach prior‑use history and any supporting clinical notes to the authorization form.
    Documentation Required

    Required prior-use documentation

    Clinical documentation must show prior use of specified generic agents appropriate to the indication (antidepressant lists or the neuropathic pain/fibromyalgia/chronic musculoskeletal pain lists) before a target drug is authorized.

    • Documentation must indicate which prerequisite list applies and which agents were tried.
    Documentation Required

    Required prior trials

    Documentation should show prior trials of the specified generic medications appropriate to the indication; the number and identity of required generics vary by drug and indication (typically two distinct generics for many targets; Lybalvi exception noted).

    • Where two generics are required, they should be distinct generic products from the program list.
    Documentation Required

    Required prior-use documentation

    Providers must document prior use of specified generic medications or indication‑specific alternative agents when submitting an authorization request; this documented prior use serves as the step‑therapy evidence.

    • Prior‑use documentation may include pharmacy records, prior authorization notes, or clinical progress notes showing trials and outcomes.
    Documentation Required

    Required documentation of prior medication trials

    Documentation must show prior use of specified generic medications tailored to the indication: prior antidepressant trials for depressive indications, or the listed neuropathic pain/fibromyalgia/chronic musculoskeletal pain agents when those are the treated conditions.

    • For chronic musculoskeletal pain, acceptable prior agents include acetaminophen, NSAID (oral or topical), amitriptyline, cyclobenzaprine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol.
    Documentation Required

    Required prior medication documentation

    Documentation of prior trials of the specified generic medications (listed by class/condition) is required to meet the Responsible Steps Program prerequisite criteria; include agent names and dates of use.

    • If prior trials are not documented, the authorization may be denied.
    Documentation Required

    Required prior-use evidence

    Submit prior‑use history showing trials of the specified generic medications; the number of distinct generics required depends on the target drug (commonly two generics; Lybalvi requires only one).

    • Include sufficient clinical detail to demonstrate that prior agents were used and failed or were not tolerated when appropriate.
    Note

    Authorization forms

    Providers should reference and use the Authorization Forms page for the specific therapeutic‑category document when submitting authorization requests and include the required prior‑use documentation per the program lists.

    • Selecting the correct therapeutic category form (e.g., Antidepressants) ensures the request maps to the applicable prerequisite lists.
    Denial Risk

    Prior use requirement

    Failure to document prior use of the required generic agents (per the program’s prerequisite lists) may result in denial of the authorization request.

    • Denial risk applies when required number or type of prior generic trials is not shown.
    Denial Risk

    Missing prerequisite trials

    If prerequisite trials are missing from the submission (for example, absence of documentation showing two or more prior generic trials where required), the authorization may be denied.

    • Ensure all applicable prior trials from the program lists are documented to reduce denial risk.
    Denial Risk

    Prerequisite generic therapy documentation

    Failure to document previous use of required generic agents (including indication‑specific alternatives for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may trigger denial of authorization.

    • Include documentation that clearly indicates which agents were used and the dates/duration.
    Denial Risk

    Prior use prerequisite

    Failure to document prior use of required generic agents for the indicated therapeutic category (e.g., antidepressants or neuropathic pain agents) may lead to denial of the authorization request.

    • Lybalvi’s single‑generic exception must still be documented when claimed.
    Denial Risk

    Missing prerequisite trials

    Failure to document required prior trials (two or more generics where applicable, or the condition‑specific alternatives) may result in non‑authorization of the requested target drug.

    • Providers should include prior‑use evidence (pharmacy fills, prior authorizations, clinical notes) to demonstrate trials occurred.
    Denial Risk

    Prior-use prerequisites

    Failure to document prior use of required generic drugs (two or more where specified) from the program lists may trigger denial of authorization.

    • Denials commonly occur when the submitted record lacks clear evidence of prior trials from the enumerated lists.
    Denial Risk

    Prior-use requirement

    Lack of documented prior use of required generic agents for the indicated condition may result in denial; ensure the authorization includes prior‑use history aligned to the applicable prerequisite list.

    • Document prior trials for antidepressant, neuropathic pain, fibromyalgia, or chronic musculoskeletal pain indications as applicable.
    Documentation Required

    Prior-use documentation required

    If the listed generic alternatives for the indication are not documented as previously used (e.g., two or more generics for antidepressants/antipsychotics or the appropriate pain agents), the authorization is at risk of denial.

    • Providers should explicitly reference which prerequisite branch (antidepressant vs pain indication) is met in the submission.
    Denial Risk

    Antipsychotic prior trials

    Failure to document previous use of two or more generic versions of listed antipsychotics (unless claiming the Lybalvi exception) may result in non‑approval of the authorization.

    • When Lybalvi is requested, include documentation of one prior generic antipsychotic trial as specified.
    Denial Risk

    Prior-use documentation required

    Failure to document prior use of required generic agents per the prerequisite lists may trigger denial of authorization for Responsible Steps Program drugs.

    • Confirm submission includes adequate prior‑use evidence to meet the stated two‑generic (or exception) requirements.
    Denial Risk

    Missing prerequisite trials

    Failure to document prior use of the required generic alternatives (for example, two or more generics for listed antidepressants/SNRIs or the specific agents for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may lead to denial.

    • Provide objective evidence of prior trials (e.g., fill history, clinic notes) to substantiate the request.
    Denial Risk

    Prerequisite generics not met

    Lack of documented prior use of required generic drugs (commonly two or more generics) may trigger denial of the authorization request for target program drugs.

    • Providers should ensure prior‑use documentation is complete and clearly matches the program lists.
    Denial Risk

    Missing prerequisite medication trials

    Failure to document previous use of required generic therapies for the indicated condition (antidepressants, neuropathic pain agents, fibromyalgia agents, or chronic musculoskeletal pain agents) may trigger denial of authorization.

    • Include agent names, dosing, dates, and clinical rationale for discontinuation or failure.
    Denial Risk

    Missing prerequisite trials

    Failure to document prior use of required generic agents (two or more where specified, or condition‑specific alternatives) may result in denial of coverage for the requested target drug.

    • If prior trials cannot be documented, provide clinical justification and supporting records explaining why the prerequisites cannot be met.
    Documentation Required

    Prior-use documentation required

    Failure to document previous use of required generic agents from the program lists may trigger denial of authorization; ensure prior‑use evidence is attached to the authorization form.

    • Attach pharmacy fill history or clinical notes showing prior trials and outcomes.
    Denial Risk

    Prior-use requirement

    Failure to document prior use of two or more generic agents in the listed classes (or the specific alternative prior agents for neuropathic pain, fibromyalgia, or chronic musculoskeletal pain) may result in denial of the authorization request.

    • Documenting the required number of distinct generic trials reduces the risk of denial.
    Note

    Definitions & Key Terms

    Prerequisite Drugs — Prior-use requirement
    RequirementPrior documented use of specified generic medications is required before authorizing target drugs; for most antidepressant and antipsychotic targets this means prior trials of two or more distinct generic agents from the listed classes.
    Lybalvi exceptionLybalvi requires documentation of only one prior generic antipsychotic rather than two.
    DocumentationProviders must submit prior-use history showing trials of the specified generic medications appropriate to the indication (see indication-specific lists).
    Gabapentin ER examples
    Gabapentin ER examplesGabapentin once-daily (generic Gralise), Gralise, and Horizant are listed as gabapentin extended‑release (ER) products in the program.
    IR prerequisite for ERPrior use of generic immediate‑release gabapentin is noted as a prerequisite for gabapentin ER in some contexts.
    Authorization formsRefer to the program authorization forms (search by therapeutic category) for submission instructions for gabapentin ER requests.
    Target Drug — Responsible Steps Program targets
    DefinitionTarget drugs are the branded or specialty products included in the Responsible Steps Program for which prerequisite prior‑use documentation is required (examples include numerous antidepressants, antipsychotics, and gabapentin ER products).
    ExamplesProgram target examples listed include: Aplenzin, Celexa, Desvenlafaxine ER (Pristiq), Effexor XR, Lexapro, Cymbalta, Abilify, Geodon, Invega, Lybalvi, Seroquel, Zyprexa, Gralise, Horizant.
    ActionPrior authorization using the program‑specific authorization forms is required for listed target drugs; providers should select the therapeutic category document on the payer page.
    Neuropathic pain prior‑use
    Required prior agentsFor neuropathic pain indications: previous use of generic amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline is required before authorizing program target drugs for neuropathic pain.
    Number of trialsDocumentation should show prior trial(s) of one or more of the listed neuropathic pain agents (the neuropathic list is an indication‑specific alternative to the general antidepressant list).
    Submit evidenceProviders must document prior use(s) of the specified generic neuropathic agents on the authorization form to meet prerequisite criteria.
    Fibromyalgia prior‑use
    Required prior agentsFor fibromyalgia: previous use of generic amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol is required before authorizing program target drugs for fibromyalgia.
    Indication‑specific listOne or more agents from the fibromyalgia list satisfy the prerequisite for that indication (OR branch to indication‑specific prerequisites).
    DocumentationClinical documentation must show prior use of the listed generic agents appropriate to fibromyalgia when submitting an authorization request.
    Chronic musculoskeletal pain prior‑use
    Required prior agentsFor chronic musculoskeletal pain: previous use of generic acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an oral or topical NSAID, or tramadol is required.
    One‑agent prerequisiteOne or more of the listed agents appropriate to chronic musculoskeletal pain fulfills the prerequisite for that indication.
    Evidence to submitProviders should document prior trials of the relevant generic analgesic/muscle relaxant/antidepressant/NSAID agents on the authorization form.
    Prerequisite drugs / previous use
    General rulePrior use of specified generic medications (typically two or more distinct generics) from the enumerated therapeutic lists is required before coverage of program target drugs; number required varies by drug and indication.
    Indication‑specific alternativesFor neuropathic pain, fibromyalgia, and chronic musculoskeletal pain the document provides alternate single‑agent lists that satisfy prerequisites for those indications.
    Provider actionSubmit prior‑use history documenting the required number and identity of prior generics per the therapeutic/indication lists when requesting authorization.
    Prerequisite drugs — Listed generic agents
    Listed genericsPrerequisite drugs include generic antidepressants (bupropion, citalopram, desvenlafaxine ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, mirtazapine, paroxetine, sertraline, trazodone, venlafaxine/ER, vilazodone) and antipsychotics (aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone).
    Pain‑related genericsPrerequisite lists also include tricyclics and other analgesic agents (amitriptyline, desipramine, imipramine, nortriptyline), gabapentin, cyclobenzaprine, NSAIDs, acetaminophen, and tramadol depending on indication.
    ApplicationThese generic medication lists must be referenced and prior‑use documented to meet step‑therapy prerequisites for the corresponding target drug/indication.
    Target Drug / Prerequisite Drugs
    Definition — Target vs prerequisiteTarget drugs are the branded or specialty products included in the Responsible Steps Program; prerequisite drugs are the specified generic agents (or alternative agents by indication) whose prior use must be documented before authorizing the target drug.
    Examples of target drugsExamples of target drugs include many antidepressants (e.g., Cymbalta, Lexapro), antipsychotics (e.g., Abilify, Seroquel, Zyprexa), and gabapentin ER formulations (Gralise, Horizant).
    How it worksAuthorization requires documentation that prerequisite (generic) trials were completed as listed; refer to therapeutic‑category authorization forms for submission details.
    Prerequisite drugs — Previously tried generics
    Trial requirementSpecified generic medications listed by class/indication must have been previously tried and documented before a program target drug will be authorized.
    Variation by indicationThe specific prerequisite list and number of prior trials required depend on the treated indication (antidepressant vs neuropathic pain vs fibromyalgia vs chronic musculoskeletal pain).
    Denial riskFailure to document prior use of the required generic agents (e.g., two or more generics where specified) may result in denial of authorization.
    Prerequisite drugs — Indication‑specific lists
    Classes includedPrerequisite lists vary by indication and include antidepressants, antipsychotics, gabapentin ER examples, tricyclics, SNRIs, SSRIs, muscle relaxants, NSAIDs, acetaminophen, and tramadol.
    Antipsychotic ruleFor antipsychotic targets the usual requirement is prior use of two or more generic versions of listed antipsychotics; Lybalvi is an explicit exception requiring only one generic.
    Indication mappingWhen the requested target drug is for a pain indication, use the corresponding pain prerequisite list rather than the general antidepressant list.
    Lybalvi exception
    Lybalvi special caseLybalvi requires documentation of only one prior generic antipsychotic trial, explicitly noted as an exception to the general two‑generic requirement.
    General antipsychotic ruleMost antipsychotic target drugs require prior use of two or more generic antipsychotics from the listed agents (aripiprazole, clozapine, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone).
    Documentation impactEnsure documentation clearly identifies the prior generic antipsychotic(s) and dates to support Lybalvi or other antipsychotic authorization requests.
    Neuropathic pain prerequisites
    Neuropathic pain listPrevious use of generic amitriptyline, desipramine, duloxetine, gabapentin, imipramine, or nortriptyline is required when the requested drug is for neuropathic pain.
    Use in authorizationIf neuropathic pain is the indication, provide prior‑use documentation of one or more listed agents instead of the general antidepressant two‑generic requirement.
    Where citedThis neuropathic pain prerequisite is presented repeatedly across the program criteria as an indication‑specific alternative list.
    Fibromyalgia prerequisites
    Fibromyalgia listFor fibromyalgia, previous use of generic amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, or tramadol is required.
    Alternative to antidepressant listWhen the indication is fibromyalgia, the fibromyalgia‑specific list satisfies the prerequisite in place of the general antidepressant two‑generic requirement.
    Documentation noteInclude prior‑use dates and agent names from the fibromyalgia list on the authorization form to meet prerequisite criteria.
    Chronic musculoskeletal pain prerequisites
    Chronic musculoskeletal pain listFor chronic musculoskeletal pain, previous use of generic acetaminophen, amitriptyline, cyclobenzaprine, desipramine, duloxetine, gabapentin, imipramine, nortriptyline, an oral or topical NSAID, or tramadol is required.
    Indication‑specific fulfillmentOne or more agents from this chronic musculoskeletal pain list satisfies the prerequisite when that is the treated condition.
    Provider documentationDocument prior trials of the relevant agents (agent name and trial date) when submitting prior authorization for chronic musculoskeletal pain indications.
    Prerequisite Drugs — General summary
    SummaryGeneric medications listed by class/indication must have been previously used and documented before approving program target drugs; the number required varies by target drug and indication (commonly two or more generics; Lybalvi requires one).
    Examples of classesClasses include antidepressants (SSRIs/SNRIs), antipsychotics, gabapentin/gabapentin ER, tricyclics, muscle relaxants, NSAIDs, acetaminophen, and tramadol.
    Provider stepReview the indication‑specific prerequisite list in the authorization form and attach prior‑use evidence for the listed generics to avoid denial.

    Background

    This document lists the drugs included in Florida Blue’s Responsible Steps Program and specifies that prior authorization for those target drugs is contingent on documented prior use of specified generic medications. For many antidepressant and antipsychotic targets the requirement is prior use of two or more generic agents from the listed options; for certain pain-related indications alternative single-agent generic lists are acceptable (e.g., neuropathic pain, fibromyalgia, chronic musculoskeletal pain). Gabapentin ER products (Gralise, Horizant) are included and in some contexts require prior use of generic immediate‑release gabapentin.

    Revision History